12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avastin bevacizumab: Postmarketing study data

There were no significant differences in the risk of myocardial infarction (MI) or ischemic cerebrovascular accident between treatment groups. The authors of the study said the data suggest differences in the safety profiles of the drugs; however, they said the study was "limited by incomplete information on some important confounding factors e.g., smoking, lipid and blood pressure levels, which would further clarify the relative safety of these treatments in wet AMD." Data...

Read the full 339 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >